Sharikas hired to attract Life Science companies to Greater Richmond

The Greater Richmond Partnership (“GRP”) has hired Kiryako Sharikas to join the team as Business Development Manager – Life Sciences. Sharikas will focus on targeting life science and pharmaceutical companies interested in expanding to the Richmond Region.

“Kiryako’s experience in marketing will translate well as he markets the region as the #1 mid-sized location in the U.S. for life science companies to invest,” said Jennifer Wakefield, President + CEO of the Greater Richmond Partnership. “With Kiryako on the team, GRP will now have a dedicated point of contact to expand the shared effort to make our region the capital of advanced pharmaceutical manufacturing.”

Sharikas has more than eight years of experience in digital marketing for employers including CoStar Group, Sheltering Arms, and NetSearch. Sharikas’ experience will be a major asset as he transitions to the new role. Sharikas is a graduate of Virginia Commonwealth University and Reynolds Community College.


Read more here.

Recent News


Protected: Don’t Miss These Spring Talent Events

There is no excerpt because this is a protected post.


SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.


ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide